Skip to content
BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Cyanotech Corp. CYAN

16 fiscal years on record · USD · FY2024 reported · SEC filings only
$24.2M
▲ 5.0% YoY
$-3.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 24.2M
Revenue, FY2024 · full 16-year series below
Revenue $M Net income $M
FY2024 · Revenue 24.2 · Net income -3.2
15M30M-2M-4M
200920122015201820212024
Compound annual growth
−12.4%
−5.4%
−3.3%
+2.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −5.4% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−13 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -10.4% · Net -13.2%
5%10%-10%-20%
200920162024
ROE
FY2024 · ROE -30.9%
10%20%-10%-20%-30%
200920162024
Three returns, three denominators.

Each USD of equity lost 31 cents this year.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2018 · FCF -1.3
2M3M-2M-3M
200920162024

Total assetsUSD 23.5M
EquityUSD 8.9M
CashUSD 257,000.00
Gross debtUSD 3.9M
Net debtUSD 3.6M
Current ratio1.03×

Net debt stands at 41% of equity.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CYAN, 16-year financial record
Metric 2024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.00.00.00.0−0.00.0−0.0−0.00.0−0.00.00.00.00.0
EBITDA $B−0.0−0.0−0.00.00.00.0−0.00.00.00.00.00.00.00.00.00.0
Income tax $B0.00.00.00.00.00.00.0−0.00.00.00.00.0−0.0−0.0−0.00.0
Net income $B−0.0−0.0−0.00.00.00.0−0.00.0−0.0−0.0−0.0−0.00.00.00.00.0
Free cash flow $B◌◌◌◌◌◌−0.00.00.0−0.0−0.0−0.0−0.00.00.00.0
EPS, diluted $◌−0.81−0.550.350.150.06−0.620.18−0.21−0.790.00−0.080.740.660.320.26
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %−30.9−37.4−19.211.85.62.5−21.85.9−7.1−22.4−0.1−2.123.527.617.115.3
Shares out B0.010.010.010.010.010.010.010.010.010.010.010.010.010.010.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 77 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onOTC market
Incorporated inNevada
Fiscal year endsMarch 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image